Institution: National Cancer Center Hospital East

0:04:09

MEDICINE AT THE NATIONAL CANCER CENTER HOSPITAL

0:00:54

Perioperative pembrolizumab for stomach cancer treatment

0:01:17

The evolving role of biomarkers in targeted gastric cancer treatment

0:00:52

The significance of tucatinib + trastuzumab as a chemotherapy-free option for HER2+ metastatic BTC

0:01:04

What remaining challenges are there in the management of rectal cancer?

0:02:29

Overcoming resistance to immunotherapy as first-line therapy in gastric cancer

0:01:17

DS-7300 demonstrates durable antitumor activity in advanced solid tumors

0:01:01

New combination therapies in HER2-expressing gastric cancer

0:01:20

Sheikha Jawaher Al Qasimi visits Cairo’s National Cancer Institute Hospital | JAIHIND TV

0:00:58

Setanaxib and pembrolizumab in head and neck squamous cell carcinoma

0:02:59

The future of gastric cancer treatment beyond ESMO 2023

0:01:03

Novel treatments for gastric cancer

0:01:35

Therapeutic strategies to overcome HER2 resistance in gastric cancer

0:03:05

Advaned RET-rearranged NSCLC

0:03:21

Advancements in cellular therapy for GI cancers

0:01:14

DESTINY-Gastric05: first-line T-DXd ± pembrolizumab in HER2+ gastric cancer

0:01:23

Phase II trial of telisotuzumab adizutecan in HER2- G/GEJ cancer & GEA

0:01:22

3-year follow-up of CheckMate 649: nivolumab + chemotherapy in GC/GEJC/EAC

0:01:35

KEYNOTE-061: association between gene expression signatures & outcomes

0:01:14

Gastric cancer updates at ESMO 2022

0:02:21

SGNTUC-019: tucatinib + trastuzumab for previously treated HER2+ metastatic biliary tract cancer

0:01:52

IILUSTRO: zolbetuximab, mFOLFOX6, and nivolumab combinations for gastrointestinal cancer

0:03:26

Best hospitals for Cancer Treatment in Japan?